Jirapinyo et al97 revealed that combination therapy, with endoscopic gastric remodeling (EGR) and GLP-1 agonists yielded greater improvements in fibrosis compared to EGR monotherapy group [ALT: reduction by 55±23% vs. 29±22% (p=0.008), NAFLD fibrosis score: reduction by 181±182% vs. 30±83% (p=0.04), liver stiffness measurement on transient elastography: reduction by 54±12% vs. 14±45% (p=0.05)] in addition to a larger reduction in weight loss [18.2±6.6% total weight loss (TWL) vs. 9.6±3.3% TWL (p=0.004)]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.